Oncolytics’ Chinese partner presents interim data on breast cancer candidate

Oncolytics Biotech’s Chinese partner Adlai Nortye announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were presented at the San Antonio Breast Cancer Symposium. Fifteen patients were treated in the trial as of the data cut-off date. Disease control, partial response or stable disease was achieved in 13 of 14 evaluable patients – 93% -, with 12 – 86% – showing tumor shrinkage from baseline.7 of 14 evaluable patients achieved a PR – 50% -. Three of these patients achieved a confirmed PR – 20% -, while two patients are awaiting potential confirmatory scans. One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study. Evolving median progression-free survival (PFS) for trial participants as of the data cut-off date was 9.1 months. The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events reported to date. Oncolytics expects to report overall response rate, PFS, and evolving overall survival data from BRACELET-1 at a major medical meeting in the first half of 2023.